This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
*Naive patients prescribed by all specialties. ELIQUIS has been the #1 prescribed OAC by naive Rx every month since November 2016.
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with NVAF. ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy.
Download resources to help support you and your patients, including dosing information, coverage support, and what to expect during treatment.
Our live specialists are just a phone call away and ready to help you and your patients.
1-855-ELIQUIS (354-7847)
Monday–Friday, 8 AM–8 PM ET
Get the information you and your patients need when considering ELIQUIS, including clinical data, access support, and what to expect during treatment.
Your patients may be eligible for a free 30-day trial and a $10 co-pay card* for their ELIQUIS prescriptions.†
*For commercially insured patients. Annual maximum benefit of $6,400. †ELIGIBILITY AND TERMS AND CONDITIONS apply.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.